Find verified Tucatinib API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Tucatinib for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Tucatinib API.
Alternate Names: Irbinitinib, Tukysa, tucatinibum
CAS No: 937263-43-9
PubChem CID: 51039094
Mol Formula: C26H24N8O2
Mol Weight: 480.5 g/mol
IUPAC Name: 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
API Description: Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
